Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD.
J Vasc Surg. 2023 Feb;77(2):454-462.e1. doi: 10.1016/j.jvs.2022.08.033. Epub 2022 Sep 1.
At present, no data are available to support the use of tibial interventions in the treatment of claudication. We characterized the practice patterns surrounding tibial peripheral vascular interventions (PVIs) for patients with claudication in the United States.
Using 100% Medicare fee-for-service claims from 2017 to 2019, we conducted a retrospective analysis of all patients who underwent an index PVI for claudication. Patients with any previous PVI, acute limb ischemia, or chronic limb-threatening ischemia in the preceding 12 months were excluded. The primary outcome was the receipt or delivery of tibial revascularization during an index PVI for claudication, defined as tibial PVI with or without concomitant femoropopliteal PVI. Univariable comparisons and multivariable hierarchical logistic regression were used to assess the patient and physician characteristics associated with the use of tibial PVI for claudication.
Of 59,930 Medicare patients who underwent an index PVI for claudication between 2017 and 2019, 16,594 (27.7%) underwent a tibial PVI (isolated tibial PVI, 38.5%; tibial PVI with concomitant femoropopliteal PVI, 61.5%). Of the 1542 physicians included in our analysis, the median physician-level tibial PVI rate was 20.0% (interquartile range, 9.1%-37.5%). Hierarchical logistic regression suggested that patient-level characteristics associated with tibial PVI for claudication included male sex (adjusted odds ratio [aOR], 1.23), increasing age (aOR, 1.30-1.96), Black race (aOR, 1.47), Hispanic ethnicity (aOR, 1.86), diabetes (aOR, 1.36), no history of hypertension (aOR, 1.12), and never-smoking status (aOR, 1.64; P < .05 for all). Physician-level characteristics associated with tibial PVI for claudication included early-career status (aOR, 2.97), practice location in the West (aOR, 1.75), high-volume PVI practice (aOR, 1.87), majority of practice in an ambulatory surgery center or office-based laboratory setting (aOR, 2.37), and physician specialty. The odds of vascular surgeons performing tibial PVI were significantly lower compared with radiologists (aOR, 2.98) and cardiologists (aOR, 1.67; P < .05 for all). The average Medicare reimbursement per patient was dramatically higher for physicians performing high rates of tibial PVI (quartile 4 vs quartile 1-3, $12,023.96 vs $692.31 per patient; P < .001).
Tibial PVI for claudication was performed more often by nonvascular surgeons in high-volume practices and high-reimbursement settings. Thus, a critical need exists to reevaluate the indications, education, and reimbursement policies surrounding these procedures.
目前,尚无数据支持在治疗跛行时采用胫骨介入治疗。我们描述了美国跛行患者胫骨外周血管介入(PVI)治疗的实践模式。
使用 2017 年至 2019 年 100%的 Medicare 按服务收费数据,对所有接受 PVI 治疗跛行的患者进行了回顾性分析。排除了在之前 12 个月内有任何先前的 PVI、急性肢体缺血或慢性肢体威胁性缺血的患者。主要结局是在 PVI 治疗跛行期间接受或提供胫骨血运重建,定义为胫骨 PVI 伴或不伴股腘 PVI。采用单变量比较和多变量分层逻辑回归来评估与胫骨 PVI 治疗跛行相关的患者和医生特征。
在 2017 年至 2019 年期间接受 PVI 治疗跛行的 59930 名 Medicare 患者中,16594 名(27.7%)接受了胫骨 PVI(单纯胫骨 PVI,38.5%;胫骨 PVI 伴股腘 PVI,61.5%)。在我们分析的 1542 名医生中,中位数医生水平胫骨 PVI 率为 20.0%(四分位距,9.1%-37.5%)。分层逻辑回归表明,与胫骨 PVI 治疗跛行相关的患者特征包括男性(校正优势比[aOR],1.23)、年龄增加(aOR,1.30-1.96)、黑种人(aOR,1.47)、西班牙裔(aOR,1.86)、糖尿病(aOR,1.36)、无高血压史(aOR,1.12)和从不吸烟状态(aOR,1.64;P<0.05)。与胫骨 PVI 治疗跛行相关的医生特征包括早期职业状态(aOR,2.97)、西部的执业地点(aOR,1.75)、高容量 PVI 执业(aOR,1.87)、大多数执业在门诊手术中心或基于办公室的实验室环境(aOR,2.37)和医生专业。血管外科医生进行胫骨 PVI 的可能性明显低于放射科医生(aOR,2.98)和心脏病专家(aOR,1.67;P<0.05)。进行高比例胫骨 PVI 的医生每位患者的 Medicare 报销平均金额明显更高(四分位数 4 与四分位数 1-3,每位患者 12023.96 美元与 692.31 美元;P<0.001)。
在高容量实践和高报销环境中,胫骨 PVI 治疗跛行更多地由非血管外科医生进行。因此,迫切需要重新评估这些手术的适应证、教育和报销政策。